Roche Diagnostics: FDA 510(k) clearances across all its applicant names
FDA lists 1,338 510(k) clearances, 53 PMA and 10 De Novo decisions across the 25 applicant names Caduvo groups under Roche Diagnostics, first 1976, latest 2026. Median 510(k) review time across these names: 65 days. Since 2017 the median was 169 days, against 160 days for all cleared 510(k)s in the same product codes. Groups are curated by Caduvo from public sources listed below; FDA does not group applicants. Counts include filings made before an acquisition, and can include older filings by a business that was later sold when FDA records them under the same applicant name; see the notes on this page.
510(k) clearances per year
| Year | Clearances | Median review days |
|---|---|---|
| 2012 | 21 | 165 |
| 2013 | 18 | 136 |
| 2014 | 21 | 85 |
| 2015 | 13 | 133 |
| 2016 | 13 | 148 |
| 2017 | 16 | 123 |
| 2018 | 15 | 132 |
| 2019 | 8 | 70 |
| 2020 | 7 | 146 |
| 2021 | 10 | 152 |
| 2022 | 19 | 209 |
| 2023 | 14 | 233 |
| 2024 | 6 | 266 |
| 2025 | 18 | 176 |
| 2026 | 20 | 171 |
The 25 FDA applicant names in this group
| Applicant name | 510(k) clearances | PMA | De Novo | Years |
|---|---|---|---|---|
| Roche Diagnostics Corp. | 454 | 15 | 4 | 1999–2026 |
| Boehringer Mannheim Corp. | 340 | 1 | 0 | 1976–1999 |
| Roche Diagnostic Systems, Inc. | 296 | 0 | 0 | 1983–1999 |
| Roche Molecular Systems, Inc. | 52 | 15 | 3 | 1993–2026 |
| Hoffmann-La Roche, Inc. | 49 | 0 | 0 | 1976–1985 |
| Ventana Medical Systems, Inc. | 46 | 13 | 3 | 1992–2024 |
| Disetronic Medical Systems | 17 | 0 | 0 | 1991–2001 |
| Roche Diagnostics Operations (Rdo) | 14 | 0 | 0 | 2014–2020 |
| Disetronic Medical Systems AG | 12 | 0 | 0 | 2000–2010 |
| Roche Analytical Instruments, Inc. | 11 | 0 | 0 | 1980–1980 |
| Roche Diabetes Care, Inc. | 10 | 0 | 0 | 2015–2023 |
| Genmark Diagnostics, Incorporated | 9 | 0 | 0 | 2011–2026 |
| Roche Diagnostics Operations | 7 | 2 | 0 | 2012–2025 |
| Roche Diagnostics GmbH | 5 | 2 | 0 | 1998–2026 |
| Boehringer Mannheim Italia Spa | 3 | 0 | 0 | 1994–1996 |
| Roche Diagnostics/Boehringer Mannheim GmbH | 3 | 0 | 0 | 1998–1999 |
| Roche | 2 | 1 | 0 | 2011–2012 |
| Roche Diabetes Care GmbH | 2 | 0 | 0 | 2023–2023 |
| Roche Professional Diagnostics | 2 | 0 | 0 | 2010–2015 |
| Roche Diabetes Care AG | 1 | 0 | 0 | 2012–2012 |
| Roche Diagnostics Hematology, Inc. | 1 | 0 | 0 | 2018–2018 |
| Ventana, Inc. | 1 | 0 | 0 | 1999–1999 |
| Ventana Medical Sytems, Inc. | 1 | 0 | 0 | 2011–2011 |
| Ventana Medical Systems, Inc. (Roche Tissue Diagnostics) | 0 | 3 | 0 | — |
| Roche Molecular System, Inc. | 0 | 1 | 0 | — |
Review time against the same product codes
Since 2017, 510(k)s cleared under these names took a median 169 days from FDA receipt to decision. All cleared 510(k)s in the same product codes over the same years took a median 160 days.
Top product codes
| Product code | Device | Submissions | 510(k) clearances |
|---|---|---|---|
| JJX | Single (Specified) Analyte Controls (Assayed And Unassayed) | 87 | 87 |
| JJY | Multi-Analyte Controls, All Kinds (Assayed) | 42 | 42 |
| JIX | Calibrator, Multi-Analyte Mixture | 31 | 31 |
| DKZ | Enzyme Immunoassay, Amphetamine | 27 | 27 |
| NBW | System, Test, Blood Glucose, Over The Counter | 24 | 24 |
| CGA | Glucose Oxidase, Glucose | 22 | 22 |
| LFR | Glucose Dehydrogenase, Glucose | 22 | 22 |
| JIT | Calibrator, Secondary | 20 | 20 |
| DKB | Calibrators, Drug Mixture | 19 | 19 |
| DIF | Drug Mixture Control Materials | 18 | 18 |
Plus 343 more product codes.
Review panels
- Clinical Chemistry (703)
- Clinical Toxicology (285)
- Immunology (132)
- Microbiology (132)
- Hematology (58)
- Pathology (51)
- General Hospital (23)
- General and Plastic Surgery (8)
- Anesthesiology (1)
- Medical Genetics (1)
- Neurology (1)
- Orthopedic (1)
- Radiology (1)
Most recent Roche Diagnostics 510(k) clearances
| 510(k) | Device | Applicant name | Product code | Decision date | Review days |
|---|---|---|---|---|---|
| K262938 | cobas eplex respiratory pathogen panel 3 | Genmark Diagnostics, Incorporated | QOF | 2026-10-30 | 70 |
| K260233 | Elecsys EBV IgM | Roche Diagnostics Corp. | LJN | 2026-10-02 | 249 |
| K260232 | Elecsys EBV VCA IgG | Roche Diagnostics Corp. | LSE | 2026-10-02 | 249 |
| K260221 | Elecsys EBV EBNA IgG | Roche Diagnostics Corp. | LSE | 2026-10-02 | 249 |
| K260047 | cobas Strep A Nucleic acid test for use on the cobas Liat System (07341911190); cobas Strep A Quality Control Kit (07402678190) | Roche Molecular Systems, Inc. | PGX | 2026-08-28 | 233 |
| K260045 | cobas® Cdiff Nucleic acid test for use on the cobas® Liat® System (07454945190); cobas® Cdiff Positive and Negative Control Kit for use on the cobas® Liat® System (07454970190) | Roche Molecular Systems, Inc. | OZN | 2026-08-28 | 233 |
| K261686 | Elecsys Phospho-Tau (217P) Plasma | Roche Diagnostics Corp. | SET | 2026-08-19 | 90 |
| K260021 | cobas® BV/CV | Roche Molecular Systems, Inc. | PQA | 2026-07-16 | 192 |
| K260917 | cobas CT/NG for use on the cobas 5800/6800/8800 systems; cobas TV/MG for use on the cobas 5800/6800/8800 systems | Roche Molecular Systems, Inc. | QEP | 2026-07-08 | 111 |
| K252323 | cobas pulse blood glucose monitoring system | Roche Diagnostics Corp. | PZI | 2026-06-12 | 322 |
1,328 earlier clearances. See the full list in Caduvo.
PMA and De Novo decisions
| Number | Pathway | Device | Decision date |
|---|---|---|---|
| DEN260027 | De Novo | Quantitative Hepatitis B Surface Antigen | 2026-10-20 |
| P250031 | PMA | VENTANA PTEN (SP218) RxDx Assay | 2026-06-12 |
| P240037 | PMA | VENTANA MET (SP44) RxDx Assay | 2025-05-14 |
| DEN240025 | De Novo | Kappa And Lambda Immunoglobulin Light Chain In Situ Hybridization Mrna Probe Detection Kit | 2024-12-05 |
| P230018 | PMA | VENTANA CLDN18 (43-14A) RxDx Assay | 2024-10-18 |
Recalls
576 product recalls in 269 recall events under these names; 19 initiated in the last five years.
14 product recalls in 2 recall events filed under other recalling-firm names cite a 510(k) or PMA held under these applicant names; 0 initiated in the last five years. Most often: Roche Insulin Delivery Systems Inc. (13), Cardinal Health Inc. (1).
These recall records list the clearance number, so the device was cleared under this name. The recalling firm may be the same company under another spelling, a company that acquired the product line, a relabeler or a contract manufacturer. They are not added to the count above.
Recalling firms are matched to the applicant names above by name only, so recalls filed under other names are not counted. A recall count says nothing about how safe one company's devices are compared with another's.
Device clinical trials
ClinicalTrials.gov lists 66 device studies (13 active or recruiting) with an industry lead sponsor under the 1 sponsor name below. Most recent:
- NCT07843485: A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (Hoffmann-La Roche; Recruiting, started 2026-10-09)
- NCT07843498: A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity (Hoffmann-La Roche; Recruiting, started 2026-09-30)
- NCT07843472: A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease (Hoffmann-La Roche; Recruiting, started 2026-09-30)
- NCT07416526: A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A (Hoffmann-La Roche; Recruiting, started 2026-05-15)
- NCT07416604: A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A (Hoffmann-La Roche; Recruiting, started 2026-04-27)
| Lead sponsor name on ClinicalTrials.gov | Device studies |
|---|---|
| Hoffmann-La Roche | 66 |
Sponsor names are matched to the applicant names above by name, with punctuation and legal suffixes removed, plus sponsor names reviewed for this group. Studies listed under other sponsor names are not counted.
How this group is built
Groups are curated by Caduvo from public sources listed below; FDA does not group applicants. Counts include filings made before an acquisition, and can include older filings by a business that was later sold when FDA records them under the same applicant name; see the notes on this page.
Boehringer Mannheim (1998), Disetronic (2003), Ventana Medical Systems (2008), GenMark (2021). Includes filings made before each acquisition. HOFFMANN-LA ROCHE is the parent's own 1976–1985 filings. Left out: Roche Medical Electronics (1970s monitoring business, later sold) and two small names with unclear history.
Sources
- https://en.wikipedia.org/wiki/Roche_Diagnostics
- https://en.wikipedia.org/wiki/Ventana_Medical_Systems
- https://en.wikipedia.org/wiki/Boehringer_Mannheim
Frequently asked questions
How many FDA 510(k) clearances are listed across Roche Diagnostics's applicant names?
FDA lists 1,338 510(k) clearances, 53 PMA and 10 De Novo decisions across the 25 applicant names Caduvo groups under Roche Diagnostics, first 1976, latest 2026. FDA records each applicant name separately; Caduvo adds up the names listed on this page.
Which FDA applicant names does Roche Diagnostics file under?
The names with the most 510(k) clearances in this group are Roche Diagnostics Corp. (454); Boehringer Mannheim Corp. (340); Roche Diagnostic Systems, Inc. (296); Roche Molecular Systems, Inc. (52); Hoffmann-La Roche, Inc. (49). The full list of 25 names is on this page.
How long does FDA take to clear Roche Diagnostics 510(k)s?
The median time from FDA receipt to decision across 510(k)s cleared under these names is 65 days. Since 2017 the median was 169 days, against 160 days for all cleared 510(k)s in the same product codes.
Does the Roche Diagnostics count include acquired companies?
Yes. A group includes filings an acquired business made under its own name, including before the acquisition. Businesses that were sold are left out, and names whose ownership is unclear are not included. FDA does not group applicants; the sources for each grouping are listed on this page.
How many device clinical trials does Roche Diagnostics sponsor?
ClinicalTrials.gov lists 66 device studies (13 active or recruiting) with an industry lead sponsor under 1 sponsor name Caduvo groups under Roche Diagnostics. ClinicalTrials.gov names the sponsor on each study; Caduvo adds up the names listed on this page.
Next steps
- See all 1,338 Roche Diagnostics clearances with predicates and recalls
- Run predicate analysis for product code JJX, Roche Diagnostics's most frequent
Compiled by Caduvo from public U.S. government records. Counts cover filings under the applicant names shown on this page only. Review days run from FDA receipt to decision. Not reviewed or endorsed by FDA or any other agency, or by the companies named. Not regulatory advice. Report an error in this grouping or data. Data and corrections policy.
All parent companies · FDA device companies by applicant name · FDA product code lookup